M. Levy (Middlesex, United Kingdom), S. Walker (Warwick, United Kingdom)
Asthma know-how and approach among Pakistani family physicians (FPs) and the impact of an educational program
A. S. Haque, A. Shiraz, F. F. Zuberi, I. Karim (Karachi, Pakistan)
|  |
Stakeholders views on the role of a respiratory general practitioner with a special interest service
M. Moffat, J. Cleland, A. Peel, S. Williams, D. Price, A. Sheikh, H. Pinnock (Aberdeen, Leicester, London, Edinburgh, United Kingdom)
| |
Patient perception of the asthma APGAR tool
B. P. Yawn, R. A. Yawn (Rochester, United States Of America)
| |
Local audit analysing the completeness of inpatient management of infective exacerbations of COPD against British Thoracic Society guidelines
D. M. Comer, R. P. Convery, C. S. O‘Dochartaigh (Craigavon, Co Armagh, United Kingdom)
| |
Pulmonary function of inhaled human insulin (Exubera®) in patients with type 1 diabetes: results from a 2-year study using standardized methodology
L. Kuitert, S. Klioze, J. Reis, W. Duggan, R. J. Riese, J. G. Teeter (London, United Kingdom; Groton, United States Of America)
| |
Lung function testing in the elderly – can we still use FEV1/FVC < 70% as a criterion of COPD?
A. Medbø, H. Melbye (Tromsø, Norway)
| |
Budesonide/formoterol maintenance and reliever therapy for asthma compared to conventional best practice: a randomised real-life study
M. R. Sears, L. P. Boulet, M. Laviolette, J. M. FitzGerald, T. R. Bai, N. Smiljanic-Georgijev, J. S. M. Lee (Hamilton, Quebec, Vancouver, Mississauga, Canada)
| |
Risk factors of near fatal asthma: the Lung Center of the Philippines experience
G. A. Ong-Cabrera, D. V. Diaz, V. Balanag (Quezon City, Philippines)
| |
The role of quality of life questionnaire in determining the prognosis of COPD
P. Celik, Y. Havlucu, G. Dinc, A. Sakar, A. Yorgancioglu (Manisa, Turkey)
| |
Quality of spirometric tests in Dutch general practices
T. Schermer, P. Poels, R. Akkermans, H. Vlek, W. Pieters (Nijmegen, Helmond, Netherlands)
| |
Characterizing the effects of inhaled human insulin (Exubera®) on FEV1 using disease progression modeling
J. G. Teeter, P. Lange, J. G. Tensfeldt, R. J. Riese (Groton, United States Of America; Hvidovre, Denmark)
| |
Pharmacodynamic (PD), pharmacokinetic (PK) and safety profile of formoterol delivered via two different dry powder inhalers (DPIs)
H. Dietrich, T. D. Nguyen, U. Buermann, U. Petzold, U. Munzel, J. Maus (Cologne, Bad Homburg, Germany)
| |
Results from a respiratory short-stay unit in a general hospital
A. Dorado, M. Garcia, L. Peñuela, E. Acosta, F. Miralles (Malaga, Spain)
| |
Hospital based physician assessment of knowledge, attitude and practice in the diagnosis and management of asthma guidelines
O. M. A. Panlaqui, E. S. De Guia (Quezon City, Philippines)
| |
Can allergic rhinitis be in focus of GPs in Ukraine?
B. B. Vengerov (Kiev, Ukraine)
| |
Is incidence of near-fatal asthma lowering in Spain?
J. Bellido Casado, V. Plaza, S. Bardagí, J. Cosano, A. López Viña, E. Martínez Moragón, G. Rodríguez Trigo, C. Picado, J. Sanchis (Barcelona, Córdoba, Madrid, Valencia, La Coruña, Spain)
| |
The Nijmegen questionnarie in asthma: a cross sectional study
L. E. Adolfsson, M. Rosander-Blomqvist, C. Lannering, S. Mölstad (Bankeryd, Jönköping, Sweden)
| |
Achievement of total control of asthma in clinical practice using the combination of inhaled salmeterol and fluticasone propionate
M. Trautmann, N. Banik, R. A. Jörres, W. Zachgo, C. Witt, S. Group (Munich, Geesthacht, Berlin, Germany)
| |
Determinants of long acting bronchodilator adherence in UK COPD patients
D. Price, S. V. Morant, R. Horne, D. Pettitt, T. MacDonald (Aberdeen, Haddendum, Brighton, Dundee, United Kingdom; New York, United States Of America)
| |
Bronchodilator efficacy of tiotropium in patients with mild COPD
G. Johansson, A. Lindberg, K. Romberg, L. Nordström, F. Gerken, A. Roquet (Uppsala, Luleå, Höllviken, Stockholm, Sweden)
| |